MA26621A1 - Composition pour aerosols pharmaceutiques - Google Patents

Composition pour aerosols pharmaceutiques

Info

Publication number
MA26621A1
MA26621A1 MA25536A MA25536A MA26621A1 MA 26621 A1 MA26621 A1 MA 26621A1 MA 25536 A MA25536 A MA 25536A MA 25536 A MA25536 A MA 25536A MA 26621 A1 MA26621 A1 MA 26621A1
Authority
MA
Morocco
Prior art keywords
composition
pharmaceutical aerosols
aerosols
pharmaceutical
Prior art date
Application number
MA25536A
Other languages
English (en)
Inventor
Llorca Nathalie
Louis Olivier
Cavaillon Pascal
Rosier Patrick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en
Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26621A1 publication Critical patent/MA26621A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25536A 1998-04-18 1999-04-15 Composition pour aerosols pharmaceutiques MA26621A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808152.4A GB9808152D0 (en) 1998-04-18 1998-04-18 Pharmaceutical aerosol formulation
GBGB9814709.3A GB9814709D0 (en) 1998-07-08 1998-07-08 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
MA26621A1 true MA26621A1 (fr) 2004-12-20

Family

ID=26313483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25536A MA26621A1 (fr) 1998-04-18 1999-04-15 Composition pour aerosols pharmaceutiques

Country Status (30)

Country Link
US (1) US7521042B2 (fr)
EP (1) EP1073417B1 (fr)
JP (1) JP2002512183A (fr)
KR (1) KR20010042816A (fr)
CN (1) CN1145478C (fr)
AP (1) AP2000001961A0 (fr)
AR (1) AR018183A1 (fr)
AT (1) ATE228823T1 (fr)
AU (1) AU755066B2 (fr)
BR (1) BR9909736A (fr)
CA (1) CA2328882A1 (fr)
CO (1) CO5021210A1 (fr)
DE (1) DE69904312T2 (fr)
DK (1) DK1073417T3 (fr)
EA (1) EA200000956A1 (fr)
EE (1) EE200000608A (fr)
ES (1) ES2189410T3 (fr)
HR (1) HRP20000689A2 (fr)
HU (1) HUP0101608A2 (fr)
ID (1) ID27887A (fr)
IL (1) IL139087A0 (fr)
IS (1) IS5665A (fr)
MA (1) MA26621A1 (fr)
NO (1) NO20005218L (fr)
NZ (1) NZ507619A (fr)
PE (1) PE20000433A1 (fr)
PL (1) PL343491A1 (fr)
PT (1) PT1073417E (fr)
TR (1) TR200100144T2 (fr)
WO (1) WO1999053901A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US7090831B1 (en) 1999-04-14 2006-08-15 Smithkline Beecham Corporation Pharmaceutical aerosol formulation
PT2283818T (pt) 2000-11-30 2017-10-09 Vectura Ltd Método de preparação de partículas para utilização numa composição farmacêutica
NZ526059A (en) † 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
EP1581639A4 (fr) * 2002-12-17 2006-03-08 Medimmune Vaccines Inc Pulv risation haute pression de mat riaux bioactifs
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
MXPA05012467A (es) * 2003-05-19 2006-02-22 Baxter Int Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023460A2 (fr) 2004-08-16 2006-03-02 Theravance, Inc. Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique
ES2613391T3 (es) * 2005-02-10 2017-05-24 Glaxo Group Limited Procedimientos de fabricación de lactosa que utilizan técnicas de preclasificación y formulaciones farmacéuticas formadas a partir de la misma
CA2653384C (fr) 2006-06-30 2017-03-14 Iceutica Pty Ltd Procedes de preparation de composes biologiquement actifs sous forme de nanoparticules
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2010024898A2 (fr) 2008-08-29 2010-03-04 Lutonix, Inc. Procédés et appareils pour poser un revêtement sur des cathéters à ballonnet
EP2393488B1 (fr) 2009-02-06 2019-06-19 University Of Southern California Compositions thérapeutiques comprenant des monoterpènes
LT3578169T (lt) 2009-02-26 2024-08-26 Glaxo Group Limited Farmaciniai preparatai, apimantys 4-{(1r)-2-[(6-{2-[(2,6-dichlorbenzil) oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenolį
ES2557553T3 (es) 2009-07-15 2016-01-27 Theravance Biopharma R&D Ip, Llc Forma de base libre cristalina de un compuesto de bifenilo
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CA2828833C (fr) 2010-03-03 2020-11-03 Neonc Technologies Inc. Compositions pharmaceutiques comprenant des monoterpenes
HUE035763T2 (en) * 2010-06-08 2018-05-28 Kobe Gakuin Educational Found Method of producing coated particles and coated particles
EP3173080B1 (fr) 2010-08-27 2019-12-11 Neonc Technologies Inc. Compositions pharmaceutiques comprenant des dérivés d'alcool périllylique
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
DK4374929T3 (da) 2010-12-17 2025-12-15 Univ Southern California Fremgangsmåder og anordninger til anvendelse af isoperillylalkohol
CN102366405A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂
RU2697862C2 (ru) * 2012-02-28 2019-08-21 Айсьютика Холдингз Инк. Ингаляционные фармацевтические композиции
DK2968313T3 (en) 2013-03-15 2018-04-16 Verona Pharma Plc drug combination
PL3142701T3 (pl) 2014-05-12 2018-11-30 Verona Pharma Plc Nowe leczenie
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
CN106546751A (zh) * 2016-11-16 2017-03-29 广州华弘生物科技有限公司 用于检测oct4蛋白的酶联免疫试剂盒
EP3547836B1 (fr) 2016-11-30 2024-08-21 University of Southern California Conjugué d'alcool périllylique-3-bromopyruvate et méthodes de traitement du cancer
EP3749291B1 (fr) 2018-02-08 2024-01-03 University of Southern California Procédés de perméabilisation de la barrière hémato-encéphalique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
EP0257915B1 (fr) * 1986-08-11 1993-03-10 Innovata Biomed Limited Formulations pharmaceutiques contenant des microcapsules
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0655237A1 (fr) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Composition d'aerosol medicinal
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
WO1996041628A1 (fr) * 1995-06-12 1996-12-27 Ono Pharmaceutical Co., Ltd. Granules contenant du pranlukast, procede de production des granules et procede de reduction de la cohesion du pranlukast
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions

Also Published As

Publication number Publication date
NO20005218L (no) 2000-11-10
IL139087A0 (en) 2001-11-25
AP2000001961A0 (en) 2000-12-31
DE69904312T2 (de) 2003-10-16
AU755066B2 (en) 2002-12-05
CN1145478C (zh) 2004-04-14
PL343491A1 (en) 2001-08-27
CN1305369A (zh) 2001-07-25
ATE228823T1 (de) 2002-12-15
ID27887A (id) 2001-05-03
US7521042B2 (en) 2009-04-21
HRP20000689A2 (en) 2001-02-28
CA2328882A1 (fr) 1999-10-28
NZ507619A (en) 2003-05-30
EA200000956A1 (ru) 2001-04-23
HUP0101608A2 (hu) 2002-03-28
AU3523199A (en) 1999-11-08
NO20005218D0 (no) 2000-10-17
BR9909736A (pt) 2000-12-19
CO5021210A1 (es) 2001-03-27
ES2189410T3 (es) 2003-07-01
IS5665A (is) 2000-10-13
DE69904312D1 (de) 2003-01-16
DK1073417T3 (da) 2003-03-24
PT1073417E (pt) 2003-04-30
EP1073417B1 (fr) 2002-12-04
PE20000433A1 (es) 2000-05-26
WO1999053901A1 (fr) 1999-10-28
AR018183A1 (es) 2001-10-31
EE200000608A (et) 2001-08-15
US20030157032A1 (en) 2003-08-21
TR200100144T2 (tr) 2001-06-21
JP2002512183A (ja) 2002-04-23
EP1073417A1 (fr) 2001-02-07
KR20010042816A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
MA26621A1 (fr) Composition pour aerosols pharmaceutiques
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID27415A (id) Komposisi farmaseutik
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
FI973518L (fi) Farmaseuttinen koostumus piperidinoalkanoliyhdisteille
FI991485L (fi) Uusi farmaseuttinen koostumus
IS5046A (is) Lyfjasamsetningar
NO20015175D0 (no) Farmasöytisk sammensetning
DK0920302T4 (da) Farmaceutisk aerosolsammensætning
NO20005913L (no) Legemiddelsammensetning
ID29262A (id) Komposisi farmasi
ID27201A (id) Komposisi farmasi
ID27150A (id) Sediaan levotiroksin bahan farmasi
ID29294A (id) Komposisi farmasi
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
EE200100281A (et) Analgeetiline ravimkoostis
ID25857A (id) Komposisi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
FR2779145B1 (fr) Nouvelles compositions pharmaceutiques
ID26215A (id) Komposisi farmasi
ITMI962628A0 (it) Composizione farmaceutica
ID23531A (id) Komposisi farmasi
UA2861S (uk) Форма для виливання супозиторіїв
BR1100755A (pt) composição farmacêutica
FI981567A0 (fi) Farmaseuttiset koostumukset